Cash Flow Statement (Annual)

CAA / CalAtlantic Group, Inc. Short Interest

CAA / CalAtlantic Group, Inc. Cash Flow Statement shows changes in cash positions over time. Cash Flow Statement data includes Cash from Operating Activities (CFOP), Cash from Investing Activities, and Cash from Financing Activities.

All numbers are times 1,000 except per share units.

2009 2010 2011 2012 2013 2014 2015 2016
Net Cash Provided By Used In Operating Activities
  Net Income Loss -13,786 -11,724 -16,417 531,421 188,715 215,865 213,509 484,730
Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
  Income Loss From Equity Method Investments -4,598 1,166 207 -2,090 949 -668 1,966 4,057
  Depreciation Depletion And Amortization 3,516 3,002 3,255 2,480 3,576 4,928 41,151 61,704
  Share Based Compensation 12,864 11,848 11,239 7,151 9,015 8,469 15,624 17,794
  Deferred Income Taxes And Tax Credits - - - - - - - -
  Other Noncash Income Expense - - - - - - - -
Increase Decrease In Operating Capital
  Increase Decrease In Mortgage Loans Held For Sale - - - - - - - -
  Increase Decrease In Inventory Real Estate Owned 326,062 148,706 -282,447 315,639 415,312 642,008 497,836 306,896
  Increase Decrease In Inventory Real Estate Not Owned -2,805 27,861 -19,727 31,551 43,319 33,027 -34,770 37,728
  Increase Decrease In Prepaid Deferred Expense And Other Assets 118,265 -111,496 6,212 -2,618 -965 -9,306 2,998 -5,697
  Increase Decrease In Accounts Payable -18,554 -6,592 1,113 4,617 13,325 9,314 -89,461 20,099
  Increase Decrease In Accrued Liabilities -22,576 -61,843 7,852 9,155 7,949 34,223 26,462 21,541
  Net Cash Provided By Used In Operating Activities 419,830 -80,958 -322,613 -283,116 -154,216 -362,397 -271,361 322,314
Net Cash Provided By Used In Investing Activities
  Payments To Acquire Interest In Joint Venture 28,600 39,513 14,689 57,458 24,328 10,506 91,453 29,118
  Proceeds From Dividends Received 3,524 7,640 8,593 14,530 4,763 18,010 19,582 39,735
  Payments To Acquire Businesses Net Of Cash Acquired - - - 60,752 116,262 33,770 - -
  Payments For Proceeds From Other Investing Activities 2,225 1,582 2,217 1,525 8,030 4,754 11,972 7,688
  Net Cash Provided By Used In Investing Activities -27,301 -33,455 -8,313 -105,205 -143,857 -31,020 184,674 2,929
Net Cash Provided By Used In Financing Activities
  Proceeds From Repayments Of Restricted Cash Financing Activities -9,748 -12,843 -1,559 3,347 6,565 -16,762 652 8,873
  Proceeds From Lines Of Credit - - - - - - 852,700 1,433,200
  Repayments Of Lines Of Credit - - - - - - 852,700 1,433,200
  Repayments Of Secured Debt - - - - 8,334 1,458 2,532 23,228
  Repayments Of Senior Debt - 792,389 - 49,603 - 4,971 29,789 280,000
  Proceeds From Issuance Of Senior Long Term Debt 257,592 977,804 - 253,000 300,000 300,000 - 300,000
  Payments Of Debt Issuance Costs 8,764 17,215 4,575 11,761 5,316 6,230 1,016 2,669
  Proceeds From Payments On Mortgage Credit Facilities 22,660 10,651 -16,464 -45,351 -8,708 11,454 -110,469 55,995
  Payments For Repurchase Of Common Stock - - - - - 36,781 22,073 232,520
  Payments Of Dividends Common Stock - - - - - - 4,851 18,841
  Proceeds From Payments For Stock Issuance Under Employee Stock Plans - - - - - 6,771 1,000 1,330
  Proceeds From Payments For Other Financing Activities - - - - - - -222 -200
  Net Cash Provided By Used In Financing Activities -422,815 250,225 10,077 324,354 314,809 242,519 60,888 -303,710
  Cash And Cash Equivalents Period Increase Decrease -30,286 135,812 -320,849 -63,967 16,736 -150,898 -25,799 21,533
  Cash And Cash Equivalents At Carrying Value - - 410,522 346,555 363,291 212,393 186,594 208,127
  Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents - - - - - - - -

Peers - Operative Builders (1531)

Related Articles

BLDP: Ballard Power Systems Analysis and Research Report

2018-08-13 - Asif

Core Business At Ballard, Ballard Power Systems is building a clean energy growth company. Ballard Power Systems is recognized as a world leader in proton exchange membrane (“PEM”) fuel cell power system development and commercialization. The company's principal business is the design, development, manufacture, sale and service of PEM fuel cell products for a variety of applications, focusing on its power product markets of Heavy-Duty Motive (consisting of bus, truck, rail and marine applications), Portable Power, Material Handling and Backup Power, as well as the delivery of Technology Solutions, including engineering services, technology transfer, and the license and sale of its extensive intellectual property portfolio and fundamental knowledge for a variety of fuel cell applications. A fuel cell is an environmentally clean electrochemical device that combines hydrogen fuel with oxygen (from the air) to produce electricity. The hydrogen fuel can be obtained from natural g...

MARA: Marathon Patent Group Analysis and Research Report

2018-08-13 - Asif

Overview Marathon Patent Group was incorporated in the State of Nevada on February 23, 2010 under the name Verve Ventures, Inc. On December 7, 2011, the company changed its name to American Strategic Minerals Corporation and were engaged in exploration and potential development of uranium and vanadium minerals business. In June 2012, the company discontinued its minerals business and began to invest in real estate properties in Southern California. In October 2012, the company discontinued its real estate business when its former CEO joined the firm and the company commenced its IP licensing operations, at which time the Company’s name was changed to Marathon Patent Group, Inc. On November 1, 2017, the company entered into a merger agreement with Global Bit Ventures, Inc. (“GBV”), which is focused on mining digital assets. Marathon Patent Group has since purchased its cryptocurrency mining machines and established a data center in Canada to mine digital assets. Following the me...

ECYT: Endocyte Analysis and Research Report

2018-08-13 - Asif

Business and Organization Endocyte, Inc. is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer. The Company uses drug conjugation technology to create novel therapeutics and companion imaging agents for personalized targeted therapies. The agents actively target receptors that are over-expressed on diseased cells relative to healthy cells, such as prostate specific membrane antigen (“PSMA”) in prostate cancer. This targeted approach is designed to safely enable the delivery of highly potent drug payloads. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. In September 2017, the Company entered into a Development and License Agreement (the “License Agreement”) with ABX advanced biochemical compounds – Biomedizinische Forschungsreagenzien GmbH (“ABX”), pursuant to which the Company acquired exclusive ...

CUSIP: 128195104